Skip to main content

Table 1 Characteristics of the study cohort

From: Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression

 

CN (n = 91)

CI (n = 127)

p-value

Demographic and clinical characteristics

 Sex, female (%)

64.4

53.9

0.12

 Age (years), mean ± SD

68.53 ± 7.31

74 ± 6.6

< 0.001

 Years of education (years), mean ± SD

13.02 ± 2.54

12.26 ± 2.78

0.04

 CDR, mean ± SD

0

0.59 ± 0.26

< 0.001

 CDRSoB, mean ± SD

0.01 ± 0.07

2.12 ± 2.14

< 0.001

 MMSE, mean ± SD

28.59 ± 1.25

25.29 ± 3.83

< 0.001

Biochemical measures

APOE ε4, n (%)

18 (21.2)

50 (43.5)

0.001

 QAlb, mean ± SD

5.45 ± 2.28

6.93 ± 3

0.002

CSF AD biomarkers

< 0.001

 Aβ1–42, pg/ml, mean ± SD

1030.62 ± 262.46

754.58 ± 287.32

< 0.001

 Tau, pg/ml, mean ± SD

301.09 ± 175.95

493.04 ± 308.79

< 0.001

 p-tau181, pg/ml, mean ± SD

57.74 ± 20.48

70.49 ± 29.77

< 0.001

 Aβ1–42/Aβ1–40

0.07 ± 0.02

0.05 ± 0.02

< 0.001

MRI

 Hippocampal volume

0.0046 ± 46E-5

0.0041 ± 57E-5

< 0.001

Plasma biomarkers

 NfL, pg/ml, mean ± SD

17.61 ± 9.24

24.66 ± 11.66

< 0.001

 p-tau181, pg/ml, mean ± SD

9.58 ± 7.09

14.78 ± 9.69

< 0.001